What is Cardarine (GW501516, non-peptide)?
A PPAR-δ agonist paired with retatrutide in fat-loss discussion.
Cardarine (GW501516, non-peptide) in the library · Metabolic & Weight Peptides · Human Trials · What are peptides?
3 registered trials · 5 indexed papers · 42 human / 164 animal studies
From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.
What it is
A PPAR-δ agonist paired with retatrutide in fat-loss discussion.
Registered human trials (3)
| Trial | Phase | Status | Year | Enrolled |
|---|---|---|---|---|
| GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol | Phase 2 | completed | 2004 | 424 |
| An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation | completed | 2004 | 71 | |
| Regulation of Lipoprotein Transport in Metabolic Syndrome | Phase 4 | completed | 2003 | 13 |
Peer-reviewed studies (5)
More cited research
- PPARδ Agonist GW501516 Suppresses the TGF-β-Induced Profibrotic Response of Human Bronchial Fibroblasts from Asthmatic Patients (2023, human observational)
- Testing for GW501516 (cardarine) in human hair using LC/MS-MS and confirmation by LC/HRMS (2020, human observational)
- Highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulator demonstrates improved safety profile compared to GW501516 (2018, human observational)
- Early controlled release of peroxisome proliferator-activated receptor β/δ agonist GW501516 improves diabetic wound healing through redox modulation of wound mi (2015, human observational)
- Selective PPARδ Agonist GW501516 Protects Against LPS-Induced Macrophage Inflammation and Acute Liver Failure in Mice via Suppressing Inflammatory Mediators (2024, animal)
- Inhibitory Effect of PPARδ Agonist GW501516 on Proliferation of Hypoxia-induced Pulmonary Arterial Smooth Muscle Cells by Regulating the mTOR Pathway (2023, animal)
- [Effects of GW501516 on the proliferation of pulmonary artery smooth muscle cells induced by hypoxia and its mechanisms] (2022, animal)
- The Role of PPARδ Agosnist GW501516 in Rats with Gestational Diabetes Mellitus (2020, animal)
Conditions researched
- Fat loss, obesity & body recomposition
- Menopause & perimenopause
- Fatty liver & elevated liver enzymes
- Insulin resistance, prediabetes & type 2 diabetes
- Atherosclerosis, cardiovascular disease & high blood pressure
- Chronic and systemic inflammation
- High cholesterol and statins
Related compounds
- Tirzepatide
- Cyanocobalamin (Vitamin B12)
- L-Carnitine
- Liraglutide
- Semaglutide
- ACTH (Corticotropin)
- BPC-157
- Exenatide
- Glutathione
- Insulin (regular human)
FAQ
What is Cardarine (GW501516, non-peptide)?
A PPAR-δ agonist paired with retatrutide in fat-loss discussion.
How many registered human trials study Cardarine (GW501516, non-peptide)?
The PeptideWhiz trial index lists 3 registered trials for Cardarine (GW501516, non-peptide), the most recent from 2004.
How much published research exists on Cardarine (GW501516, non-peptide)?
The PeptideWhiz paper index links 5 PubMed papers to Cardarine (GW501516, non-peptide); by study type, 42 human and 164 animal studies.
Which conditions is Cardarine (GW501516, non-peptide) researched for?
Fat loss, obesity & body recomposition, Menopause & perimenopause, Fatty liver & elevated liver enzymes, Insulin resistance, prediabetes & type 2 diabetes, Atherosclerosis, cardiovascular disease & high blood pressure, Chronic and systemic inflammation, High cholesterol and statins.
Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).